# Hepion Pharmaceuticals to Present at NASH-TAG 2024
Canonical URL: https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-to-present-at-nash-tag-2024-cb4d9511
Ticker: HEPA
Company: Hepion Pharmaceuticals
Source: Hepion Pharmaceuticals
Published: 2024-01-03 22:15 EST
## Summary

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on...

## Article Body
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the 2024 NASH-TAG Conference, which is being held January 4-6, 2024, in Park City, Utah.

Presentation Details

Title: Hepatic Functional Improvement Detected by HepQuant DuO within 120 Days of Treatment with Rencofilstat in MASH Subjects with ≥F3 Fibrosis.

Authors: SA Harrison, P Mayo, T Hobbs, C Zhao, C Canizares, R Foster, MP McRae, SM Helmke, and GT Everson

Date: Saturday, January 6, 2024

A copy of the presentation materials will be accessible on the Company’s website at www.hepionpharma.com under “Publications” in the Pipeline section.

About Hepion Pharmaceuticals

The Company's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models and is currently in Phase 2 clinical development for the treatment of NASH. In November 2021, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for rencofilstat for the treatment of NASH. That was followed in June 2022 by the FDA’s granting of Orphan Drug designation to rencofilstat for the treatment of HCC.

Hepion has created a proprietary Artificial Intelligence deep machine learning (“AI/ML”) platform designed to better understand disease processes and identify patients that are rencofilstat responders. This AI/ML has the potential to shorten development timelines and increase the observable differences between placebo and treatment groups. In addition, Hepion’s AI/ML can be used to drive its ongoing NASH and HCC clinical development programs and identify other potential therapeutic indications for cyclophilin inhibition with rencofilstat.

For further information, please contact:

Hepion Pharmaceuticals Investor Relations 732-902-4000
## Recent Company News
- 2026-03-03 12:35 EST — [Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-in-licenses-ctrna-biomarker-assay-to-facilitate-early-dia-5419c60d) — Source: Hepion Pharmaceuticals
- 2025-06-25 12:30 EST — [Hepion Pharmaceuticals Successfully Completes Application to the OTCQB](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-successfully-completes-application-to-the-otcqb-9ba83e8c) — Source: Hepion Pharmaceuticals
- 2025-06-16 12:30 EST — [Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-announces-dr-kaouthar-lbiati-as-interim-chief-executive-o-a94f00a0) — Source: Hepion Pharmaceuticals
- 2025-05-12 20:30 EST — [Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-announces-receipt-of-delisting-notification-from-nasdaq-b29aaf82) — Source: Hepion Pharmaceuticals
- 2025-05-07 12:30 EST — [Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-executes-binding-letter-of-intent-with-new-day-diagnostic-4fed3351) — Source: Hepion Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)